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OBJECTIVES We sought to determine whether direct stenting might prevent the adverse events associated
with stent implantation during primary angioplasty and to compare it with conventional stent
implantation in patients with acute myocardial infarction (AMI).
BACKGROUND No trial has demonstrated that stents favorably influence mortality rate. Recent studies have
even suggested a negative impact of stents on coronary blood flow and clinical outcome.
METHODS Of 409 patients treated by primary angioplasty with stent implantation in our center, 206
(50%) were enrolled in this randomized, single-center trial and allocated to direct stent
implantation (n  102) or stent implantation after balloon pre-dilation (n  104). The study
end points included angiographic results (final corrected Thrombolysis In Myocardial
Infarction [TIMI] frame count and a composite end point of slow and no-reflow or distal
embolization), an electrocardiogram marker of myocardial reperfusion assessment (ST-
segment resolution) and in-hospital clinical outcome (death and recurrent infarction).
RESULTS Direct stent implantation failed in eight patients but succeeded after pre-dilation in all. A
non-significant increase in TIMI flow grade 3 was achieved after direct stenting (95.1% vs.
93.3%, p  0.74) without significant difference in the corrected TIMI frame count (31.5 
17 and 35.2  20 frames after direct and conventional stent, respectively, p  0.42). The
composite angiographic end point was significantly reduced by direct stent implantation
(11.7% vs. 26.9%, p  0.01). ST-segment resolution was also significantly improved after
direct stent (no ST-segment resolution in 20.2% vs. 38.1% after direct and conventional stent,
respectively, p  0.01). Death and/or recurrent infarction occurred in six patients after
conventional stent implantation and in two patients after direct stenting (p  0.28).
CONCLUSIONS In selected patients with AMI, direct stenting can be applied safely and effectively. This
strategy may result in a significant reduction of microvascular injury, as suggested by improved
ST-segment resolution after reperfusion with major potential clinical consequences. (J Am
Coll Cardiol 2002;39:15–21) © 2002 by the American College of Cardiology
Several studies have evaluated the benefit of coronary stents
during primary angioplasty. Coronary stent implantation
has been shown to result in lower rates of recurrent ischemia
and subsequent target vessel revascularization after primary
angioplasty (1–4). However, no trials have demonstrated a
significant impact of coronary stents on the survival rate
after myocardial infarction (MI). The most representative
randomized trials to date even suggest that coronary stent
implantation may be associated with a slight, although
nonsignificant, increase in the mortality rate compared with
primary balloon angioplasty (5,6). Conflicting results have
been reported on the primary success rate after stent
implantation, and there is some concern as to possible
coronary blood flow degradation, with a decrease in Throm-
bolysis in Myocardial Infarction (TIMI) grade flow com-
pared with balloon angioplasty alone (1–7). Recent trials
evaluating the benefit of glycoprotein (GP) IIb/IIIa inhib-
itors in the setting of acute coronary syndrome have sug-
gested that microembolization may play a deleterious role
and have highlighted a new target of acute MI (AMI)
therapy with major implications in terms of prognosis
(8–11). Preserved left ventricular (LV) function and im-
proved outcome have been reported with the combined use
of GP IIb/IIIa inhibitors and conventional stent implanta-
tion (12,13). We hypothesized that direct stent implanta-
tion could prevent embolization and no-reflow and also
improve clinical outcome of primary angioplasty with stent
implantation. Consequently, we conducted a prospective
randomized trial comparing direct coronary stenting with
conventional stent implantation in AMI.
METHODS
Patient selection. Our institution policy is one of direct
admission to the cath-lab for all suspected AMIs managed
by pre-hospital emergency mobile units staffed by a trained
physician (Service d’Aide Me´dicalise´ d’Urgence). Conse-
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quently, patients were screened by the operator inside the
cath lab. Inclusion criteria involved patients with AMI who
presented within 12 h of symptom onset or between 12 h
and 24 h if they had persistent symptoms with evidence of
ongoing ischemia. Patients were considered for the trial if
they had either ST-segment elevation of at least 1 mm in
two contiguous electrocardiographic leads or a non-
diagnostic electrocardiogram (ECG) (including left bundle-
branch block, ST-segment depression or T-wave inversion)
with prolonged chest pain (30 min) and documentation of
MI in the catheterization laboratory (with evidence of
high-grade coronary stenosis and associated LV wall-
motion abnormalities). Patients who received pre-hospital
thrombolysis were included in the study, and patients in
cardiogenic shock were excluded. The decision to include a
patient was made after identification of the infarct-related
vessel and after successful crossing of the lesion with a guide
wire, when coronary stenting was deemed feasible. Angio-
graphic exclusion criteria were unprotected left main dis-
ease, extensive thrombus throughout the infarct-related
artery, heavy coronary calcification and target lesion located
in a saphenous vein graft. Most patients with TIMI flow 0
were included only when partial or complete reperfusion
was achieved, because sustained TIMI 0 perfusion pre-
cluded the assessment of the distal vessel bed as well as the
selection of the appropriate stent. Patients with a target
lesion located in a true bifurcation were excluded. After
giving oral informed consent in the cath lab, patients were
randomized to direct stenting or balloon angioplasty fol-
lowed by stent implantation by means of a non-blinded
allocation system.
Procedure. Percutaneous transluminal coronary angio-
plasty (PTCA) procedures were performed by six experi-
enced operators (300 to 600 PTCAs per operator, per year).
Pre-dilation was performed with a single low-pressure
inflation followed by stent implantation with a pre-mounted
stent. For direct stenting, an effort was made to use a single
stent whenever possible, with a mean stent size compatible
with both the proximal and distal reference diameter,
delivered at low pressure in cases of poor distal vessel
opacification and over-expanded when necessary if under-
sized. Pre-mounted tubular or multicellular stents were
recommended. High-pressure inflation was not performed
except in cases of non-optimal angiographic results. Intra-
vascular ultrasound guidance was not used. Prior to the
intervention, all patients received intravenous aspirin
(250 mg to 500 mg) and heparin with an activated clotting
time target of 250 s. The use of GP IIb/IIIa inhibitors was
optional in the trial, except in instances such as distal
embolization, no-reflow phenomenon and sub-optimal flow
after coronary stenting. The use of intracoronary verapamil
or adenosine was at the operator’s discretion but was
strongly recommended in cases of slow and no-reflow and
when coronary blood flow was sub-optimal. After stent
implantation, the arterial sheath (radial/femoral) was di-
rectly removed with immediate hemostasis at the femoral
access site by means of a percutaneous suture device (Per-
close Inc., Redwood City, California). A combination of
aspirin and ticlopidine (250 mg to 500 mg/day for one
month) was immediately initiated in all patients upon
leaving the cath lab.
Study end points. Study end points included the final
TIMI frame count for the number of frames required to
opacify standardized angiographic landmarks and normal-
ized for vessel length (14), a composite angiographic end
point including angiographic events such as distal emboli-
zation, slow-flow (decrease in flow from TIMI 3 to TIMI 2)
or no-reflow (decrease in flow from TIMI 2 or 3 to TIMI
0 or 1), a binary ECG criterion of microvascular reperfusion
injury as defined by the presence of persistent (50% of
initial value) ST-segment elevation 30 to 60 min after
completion of the procedure as previously described (15)
and a composite clinical end point of in-hospital mortality
and reinfarction. No core laboratory was used for the study,
but all angiographic data were centralized and analyzed
separately by a single operator. ST-segment data analysis
was carried out separately and blinded to treatment alloca-
tion. All analyses were on an intention-to-treat basis.
Statistical analysis. Statistical analysis was performed us-
ing SAS 6.08 software (Dynamic Microsystem, Inc., Lon-
don, United Kingdom). Data were summarized using the
means  SD for continuous variables and frequency for
categorical variables. Univariate analysis was performed
using Student t test or chi-square when appropriate.
RESULTS
From June 1999 to November 2000, 409 patients with AMI
were treated by PTCA with stent implantation in our
institution: 206 patients were randomly assigned (two pa-
tients were excluded because of protocol violation) to either
direct stenting (102 patients) or balloon angioplasty fol-
Abbreviations and Acronyms
ADMIRAL  Abciximab Before Direct Angioplasty
and Stenting in Myocardial Infarction
Regarding Acute and Long-term
Follow-up
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complication trial
cTFC  corrected Thrombolysis in Myocardial
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lowed by stent (104 patients). The number of patients
excluded and the reasons are shown in Figure 1. An analysis
of these exclusions showed that despite potential eligibility
many of these patients were treated by direct stenting
(non-randomized). Sustained no-flow distal to the obstruc-
tion after crossing the lesion with a guide wire accounted for
19% of the exclusions.
Procedural outcome. The baseline characteristics of the
two groups were well matched (Table 1) with an even AMI
population distribution for most of the clinical and angio-
graphic variables. Except for heparin, aspirin and ticlopi-
dine, the use of adjunctive medications was limited and
defined by protocol as rescue treatment, depending on the
angiographic results (GP IIb/IIIa inhibitors in 11.6% of the
global study population). Procedural data are listed in Table
2. All patients received a stent. Direct stent implantation
failed in eight patients in whom pre-dilation was necessary
before final and successful stenting could be achieved. The
cumulative angiographic incidence of slow-flow, no reflow
or distal embolization occurred in 12 patients in the direct
stent group and in 28 patients in the conventional stent
group (p  0.01). Timing of these adverse events relative to
the procedure are detailed in Table 2. Despite these differ-
ences, the final TIMI 3 flow grade rate was high in the two
groups, with a non-significant increase in the direct stent
arm (95.1 vs. 93.3%) and no significant difference in the
corrected TIMI frame count (cTFC) (31.5  17 vs. 35.2 
20 frames, p  0.42). Electrocardiogram analysis after
reperfusion showed no ST-segment resolution in 17 and 32
patients after direct and conventional stenting, respectively
(p  0.01). An increase in ST-segment elevation occurred
in four and nine patients (p  0.14) after direct versus
conventional stenting, respectively.
In-hospital outcome. Figure 2 shows in-hospital out-
comes. Death occurred in four patients after conventional
stenting and in one patient after direct stenting (p  0.36).
Three deaths occurred on Day 1, with suspected myocardial
rupture in two cases and ventricular fibrillation in one; one
octogenarian patient died after 12 days from progressive LV
failure. In the direct stent group, the only death occurred in
an octogenarian patient with three-vessel disease, non–Q-
wave MI and irreversible cardiogenic shock after angio-
plasty. sub-acute stent occlusion occurred in three patients
in each group (within 30 min to three days after percuta-
neous coronary intervention). Repeat angioplasty was per-
formed in these six patients, and only two had recurrent MI
(conventional stent group). Therefore, the combined clinical
end point of death and recurrent MI was 5.7% in the
conventional stent group and was not significantly higher
than the 1.9% rate reported in the direct stent group (p 
0.28). Mean hospital stay was 6.9 days in the direct stent group
and 7.4 days in the conventional stent group (p  0.89).
DISCUSSION
Patients with AMI benefit from primary angioplasty, as
shown by lower rates of mortality, recurrent infarction and
stroke compared with thrombolysis (16–18). Coronary stent
Figure 1. Selection of patients and reasons for exclusion. AMI  acute
myocardial infarction; IRA  infarct-related artery; pts  patients.
Table 1. Baseline Characteristics of the 206 Study Patients
DS
(n  102)
CS
(n  104)
p
Value
Age, yr 59.9  13 59.2  14 0.85
Men (%) 81 (79.4) 92 (88.4) 0.94
Risk factors
Hypertension 36 (35.3) 32 (30.7) 0.6
Smoker (%) 60 (58.8) 64 (61.5) 0.8
Dyslipidemia (%) 56 (54.9) 33 (31.7) 0.01
Diabetes (%) 16 (15.7) 9 (8.6) 0.18
Family history (%) 26 (25.5) 24 (23.1) 0.8
Previous infarction (%) 9 (8.8) 2 (1.9) 0.16
Previous bypass
surgery/angioplasty (%)
10 (9.9) 5 (4.8) 0.22
Anterior MI location (%) 41 (40.2) 47 (45.2) 0.73
Prehospital thrombolysis (%) 17 (16.6) 24 (23.1) 0.20
Symptom-onset time to
admission, h*
4.0 (3–24) 4.0 (3–24) 1
Multivessel disease (%) 42 (41.1) 43 (41.3) 0.90
Ejection fraction (%) 56.8  13 56.0  14 0.84
Infarct-related vessel (%)
Left anterior descending 40 (39.2) 47 (45.2) 0.74
Right coronary 44 (43.1) 38 (36.5) 0.45
Circumflex 18 (17.6) 19 (18.3) 0.71
TIMI grade flow (%)
TIMI 0 46 (45.1) 49 (47.1) 0.96
TIMI 1 8 (7.8) 9 (8.6) 0.83
TIMI 2 21 (20.6) 17 (16.3) 0.36
TIMI 3 27 (26.4) 29 (27.9) 0.70
CS  conventional stenting implantation; DS  direct coronary stenting; MI 
myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
*Median (range).
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implantation during primary angioplasty further reduces the
six-month event rate and has a major effect on the target
vessel revascularization rate (5,6). Compared with the pre-
viously reported reocclusion rates that can be as high as 15%
after balloon angioplasty for AMI, all stenting trials of
primary angioplasty have reported a lower reocclusion rate
at six months. So far no trial has established the long-term
beneficial influence of coronary stenting on mortality reduc-
tion. Even the most recent Primary Angioplasty in MI
(PAMI) stent and Stenting in Acute MI (STENTIM)-2
trials suggested a possible (nonsignificant) deleterious effect
of stent implantation after conventional balloon angioplasty
(5,6). Nevertheless, considering the demonstrated impact of
late reocclusion after balloon angioplasty on long-term
mortality, one may assume that stents may have a significant
impact on long-term survival (19). Therefore, although
definite evidence is lacking, there are many arguments in
favor of considering stent implantation on a systematic
basis. In this setting, the role of direct coronary stenting is
unknown and has never been evaluated.
Table 2. Procedural Data and Results
DS
(n  102)
CS
(n  104) p Value
Catheter balloon used, (%) 24 (23.5) 108 (107.3) 0.0001
Direct stent failure (%) 8 (7.8) — —
Stent implantation
Total number (n/patient) 126 (1.23) 120 (1.15) 0.14
Mean total length, mm 16.6  7 16.3  5 0.35
Mean diameter, mm 3.25  0.4 3.29  0.3 0.42
Mean balloon pressure, atm 13.8  2.8 12.5  2.5 0.001
Stent implanted
Bx velocity (%) 57 (45.6) 52 (43.4) 0.84
ACS multilink (%) 46 (36.8) 37 (31.1) 0.47
AVE (%) 10 (9.9) 10 (8.4) 0.89
Others (%) 13 (9.9) 21 (17.1) 0.19
Post-stent inflations (%) 52 (49.1) 40 (38.4) 0.11
Mean inflations nb (%) 2.1  1.6 2.6  1.1 0.01
Slow flow
Predilation (%) 0 3 (2.8) 0.50
Stent (%) 1 (1.9) 8 (7.6) 0.11
Post-stent (%) 2 (3.8) 2 (5.0) 0.8
Total (%) 3 (2.9) 13 (12.5) 0.02
No reflow
Predilation (%) 0 4 (3.8) 0.66
Stent (%) 2 (1.9) 2 (1.9) 0.61
Post-stent (%) 3 (5.7) 2 (5.0) 0.75
Total (%) 5 (4.9) 8 (7.6) 0.56
Distal embolization
Predilation (%) 0 5 (4.8) 0.79
Stent (%) 3 (2.9) 2 (1.9) 0.98
Post-stent (%) 1 (1.9) 0 0.88
Total (%) 4 (3.9) 7 (6.7) 0.50
Composite angiographic end point 12 (11.7) 28 (26.9) 0.01
Verapamil/adenosine (%) 24 (23.5) 33 (31.7) 0.19
Glycoprotein IIb/IIIa inhibitor (%) 11 (10.7) 13 (12.5) 0.85
Angiographic success (%) 82 (98.8) 82 (96.5) 0.64
Final TIMI flow grade 3 (%) 97 (95.1) 97 (93.3) 0.74
Mean cTFC, frames 31.5  17 35.2  20 0.42
No ST-segment resolution (%) 17 (20.2) 32 (38.1) 0.01
ST elevation majoration (%) 4 (4.7) 9 (8.6) 0.14
Peak creatine kinase, U/l 1,577  2,139 1,678  1,393 0.49
Because of rounding, not all percentages total 100.
CS  conventional stenting implantation; cTFC  corrected TIMI frame count; DS  direct coronary stenting; TIMI 
Thrombolysis In Myocardial Infarction.
Figure 2. In-hospital clinical outcome (numbers indicate percent of events)
in both study groups. Open bar  direct stent; solid bar  conventional.
Re-MI  recurrent myocardial infarction; TVR  target-vessel revascu-
larization.
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Direct stenting feasibility in AMI. Improvement in stent
profile flexibility and delivery systems with manufactor-
crimped stents permit stent implantation without pre-
dilation. Several groups have reported satisfactory results in
consecutive series of patients who underwent direct stenting
(20–23). Experimental data even suggest that direct stent-
ing may favorably affect the restenosis process and decrease
the restenosis rate (24). This study is the first clinical trial to
date focusing on the role of direct stenting in AMI and
showing that a direct stent strategy is feasible in patients
with AMI treated by primary angioplasty. Although pa-
tients were selected, no age restriction was applied, and
failure of direct stent implantation was observed in 8% of
cases, without clinical consequences. In these cases, stent
implantation was always successful after pre-dilation.
Therefore, direct stenting in AMI seems feasible, without
major limitations and safe, as was observed in our consec-
utive patients admitted for primary angioplasty. The first
and direct consequence of this direct stent strategy is the
reduction in procedure costs as demonstrated by the dra-
matic reduction in balloon-catheter use. Several reports have
also stressed the reduction in radiation exposure time and
procedural duration (22,23).
Angiographic and clinical impact of direct stenting. One
important finding of this study is that direct stenting
facilitates percutaneous revascularization and prevents
periprocedural complications compared with conventional
stent implantation with pre-dilation. The incidence of slow
reflow or no reflow as well as direct visualization of distal
embolus as possible angiographic evidence of thrombus
and/or atheromatous embolization are all reduced by the
direct approach. The composite angiographic end point is
significantly reduced compared with the conventional stent
strategy, which reflects the impact and preventive effect of
direct stenting. The positive impact of direct stenting in
reducing the no-reflow phenomenon and in preserving
microcirculation was recently suggested in a retrospective
and non-randomized comparison of direct stent implanta-
tion in AMI (25), and our results definitely confirm these
data. However, even if direct stenting does reduce the
incidence of no reflow, it must be stressed that this event
still occurs in 5% of cases after direct stenting. Additional
therapeutic measures are, therefore, necessary. Several
mechanisms may explain the preventive effect of direct
stenting. First of all, direct implantation allows a reduction
in the number of inflations, decreasing the likelihood of
thrombus and/or plaque content dislodgment and fragmen-
tation. The absence of pre-dilation before stenting may
prevent thrombus fragmentation and further plaque injury
before stent insertion, with the stent acting primarily as a
scaffold to trap the thrombus and plaque content before any
manipulation. The impact of inflation pressure on the
incidence of slow/no flow is another issue. Since distal
embolization may occur more frequently after high-pressure
stent deployment and because a higher deployment pressure
was evident in the direct stent group, a negative effect could
have been expected. Therefore, we can only speculate that a
lower stent deployment pressure would have maximized
differences in the two groups.
The final impact on epicardial reperfusion is more limited
because only a slight and non-significant difference in the
final TIMI flow grade 3 and in the cTFC was demon-
strated. However, the very high TIMI flow grade 3 rate that
we obtained in the control group only compares to the upper
limit of 78% to 98% TIMI flow grade 3 after primary
angioplasty or stenting published so far (1–7,26), which
makes any further significant improvements in TIMI flow
grade hard to achieve. The liberal use of verapamil and
adenosine in cases of slow reflow or no-reflow allowed us to
achieve a high TIMI 3 grade in both groups, which may
have mitigated larger differences in the two study groups.
We may also hypothesize that the major impact of a direct
stent strategy may not lie in the TIMI flow grade 3, which
coronary stent implantation has already achieved with better
cTFC compared with primary balloon angioplasty (27), but
in the capacity to decrease both macro- and micro-
embolization with a final and significant effect at the
microvascular level. The sensitivity of the TIMI frame
count and TIMI grade may also be too low in this case. In
contrast, ECG analysis proved to be of particular value.
Analysis of ST-segment changes is a simple and validated
technique for assessing myocardial integrity after reperfu-
sion and can be correlated to the evaluation of myocardial
perfusion defect (no-reflow) by myocardial contrast echog-
raphy (28). Our results indicate a 50% absolute reduction in
the incidence of persistent ST-segment elevation after direct
stenting. These results are clinically relevant and have major
implications given that the long-term prognosis of persis-
tent ST-segment elevation after primary PTCA has been
clearly demonstrated to be poor by Van’t Hof and Claeys
(15,29). These ST-segment course abnormalities have been
reported by Claeys et al. (15) in 36% of cases after successful
primary angioplasty with a 50% cutoff value. Matetzky et al.
(30) report the same absence of early ST-segment elevation
resolution after angiographically successful primary angio-
plasty (same cutoff value) in 24% of cases with similar
unfavorable outcome (i.e., increased in-hospital and long-
term mortality, congestive heart failure and long-term
chronic heart failure indicative of microvascular damage and
less myocardial salvage). Recently, a sub-analysis from the
Hirulog Early Reperfusion Occlusion-1 trial study demon-
strated an improved infarct zone wall motion at 48 h in
patients with TIMI 2 or 3 infarct-related vessel post-
thrombolysis and ST-segment recovery (31). The impact of
direct stenting on the resolution of ST-segment elevation
that we report suggests an improved microvascular reperfu-
sion status and less myocardial damage with potential
clinical implications. Consequently, in our study, the direct
stent strategy seems to influence the early outcome favorably
as demonstrated by a clear trend toward decreased reinfarc-
tion and mortality rates. The small study sample size
together with the low event rate after primary angioplasty
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with stenting did not allow us to demonstrate any significant
early clinical difference between the two strategies. Al-
though non-significant, the reduction in the combined
event rate of reinfarction and death that we observed after
direct stenting is in accordance with the observed effect on
ST resolution; this reduction can be compared with the
clinical benefit demonstrated in the Abciximab Before
Direct Angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-term Follow-up (ADMIRAL)
study, a positive study evaluating the role of abciximab
before direct angioplasty and stenting (13). Therefore, the
results of the study reinforce the role of stents in primary
angioplasty as reported in previous randomized stent trials
(1–6) and give further insight into the positive impact of a
stent-mediated strategy on the outcome of primary angio-
plasty. Furthermore, they give support to a strategy of
routine stenting in AMI, offsetting recent concern about the
possible deleterious role of stent—conventional implanta-
tion—in AMI. This new strategy, by preventing stent-
associated micro-embolization, may have the potential to
magnify the benefits of stent as compared with balloon
angioplasty for primary angioplasty.
Study limitations. One major limitation of the study is the
fact that the results were obtained from a single high-
volume center involving only half of the patients screened.
However, in the event of a selection bias and because most
of the exclusion criteria were angiographic (excluding situ-
ations where direct stenting may have been necessary), the
major impact of direct stenting may have been missed and
the power of the study decreased. As a consequence, the
results of the study may not be generalized to all patients
with AMI. Further trials should address the issue of direct
stenting in a larger AMI population, with a randomization
process occurring before angiography. Several major issues
have yet to be resolved. In particular, it is still not known
whether a direct stent approach can be safely applied when
the culprit artery remains totally occluded with no flow after
wire passage. The latter situation may represent a major
challenge for direct stenting in AMI. Recent technological
advances may allow the use of specific thrombectomy
devices before (direct) stenting; such a strategy could in-
crease the impact of a direct stent strategy focused on the
prevention of distal micro-embolization and improve tissue
reperfusion. Another limitation of the study is the lack of
LV assessment during follow-up. However, the early reduc-
tion in clinical events together with the substantial effect on
ST-segment recovery suggests a favorable impact of the
direct stent strategy. Long-term follow-up is pending, and
confirmation is awaited.
Additional trials are warranted in order to test adjunctive
therapies such as GP IIb/IIIa inhibitors combined with
direct stenting. The TIMI 14 study showed that patients
with a patent artery 60 min after abciximab and thrombo-
lytic therapy had a higher frequency of 70% ST-segment
resolution at 90 min (32). Conversely, the preliminary
results of the Controlled Abciximab and Device Investigation
to Lower Late Angioplasty Complication (CADILLAC)
trial do not underline any benefit in combining abciximab
with primary stenting in terms of in-hospital outcome in
1,961 randomized patients (7). However, pharmacologic
agents, when given before intervention, may improve the
outcome by opening arteries before intervention in a higher
proportion of patients amenable to direct stenting
(13,33,34).
Conclusions. Percutaneous coronary intervention for AMI
benefits from the direct use of stents without pre-dilation.
Such an approach is safe, feasible and reduces the incidence
of no-reflow or distal embolization; moreover, it may
favorably influence the outcome of primary angioplasty. A
significant effect on early ST-segment elevation resolution
after PTCA suggests that direct stenting prevents micro-
vascular damage and may improve myocardial reperfusion.
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